Abstracts co-occurrence of symptoms of Attention Defi cit Hyperactivity Disorder (ADHD), a neurobehavioral condition that impairs organization and executive planning that affects between 1-6% of adults in the United States. METHODS: The study design utilized an internet-based panel of 567 T2DM cases that consented to participate in a survey. In addition to de-identifi ed demographic data, respondents were asked to provide information on diabetes self-care, HbA1c values, ADHD symptoms, and health care resource utilization. RESULTS: The results indicated that those respondents who had symptoms of ADHD had more offi ce visits for diabetes-related issues (p .0002), more offi ce visits for illness or injury (p .0007), and more hospitalizations for illness or injury (p .0493) compared with T2DM respondents without symptoms of ADHD. For those who reported HbA1c values, regression tree analyses suggested low diabetes self-care scores and high ADHD symptom scores were associated with worse HbA1c values. CONCLUSIONS: These fi ndings suggest that the cooccurrence of T2DM and ADHD symptoms could result in poor HbA1c management and may lead to increased resource utilization. OBJECTIVES: Functioning in severe mental disorders is very important and brief rating instruments are needed. Personal and Social Performance Scale (PSP) is one of the instruments which can be used in severe mental disorders in a short time.
PMH51 PSYCHOMETRIC PROPERTIES OF THE LIFE PARTICIPATION SCALE FOR ADULTS ASSESSING DEFICITS IN ADAPTIVE FUNCTIONING
Saylor KE y 1 , Sutton V 2 , Khan SA 3 1 Neuroscience, Inc, Herndon, VA, USA, 2 i3 Research, Cary, NC, USA, 3 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: The Life Participation Scale for Children was designed to measure treatment-related improvements in adaptive functioning in children with ADHD. To measure these attributes in adult subjects, we developed a Life Participation Scale for Adults (LPS-A). METHODS: LPS-A items were selected by convening focus groups, interviewing experts, and performing structured cognitive interviews to improve item wording. These were administered in a 2-week study of treated (N 10) and untreated (N 10) participants with ADHD and normal controls (N 11). Cronbach's alpha, Lin's concordance correlation, and Pearson's correlations were used to assess internal consistency, test-retest reliability, and convergent/divergent validity. LPS-A scores were compared for ADHD/control, treated/untreated, and less/more severe participants to measure discriminant validity. RESULTS: The LPS-A demonstrated internal consistency (Cronbach's alpha 0.92-0.96). Concordance correlations indicated test-retest reliability (r 0.79 to 0.86). Convergent, divergent, and discriminant validity were demonstrated. CONCLUSIONS: The initial examination of the LPS-A suggests acceptable levels of validity and reliability. Larger studies will provide further information about the psychometric properties of the LPS-A. The LPS-A appears to be a promising new instrument for measuring adaptive function in adults with ADHD. for Drug Evaluation and Research (CDER) or directly from the company website, was used for all the drugs, including the drugs withdrawn from the market. Effi cacy endpoint data was obtained from the Clinical Studies section of the approved product label. Effi cacy measures were categorized into PRO, clinician-reported outcomes (CRO) and laboratory devices. RESULTS: During the fi ve year period, 14 of the 153 FDA-approved NMEs were CNS agents. The CNS agents included four drugs for neuromuscular disorders, two antipsychotics, two antidepressants, two sedatives, one smoking cessation drug, one analgesic, one CNS stimulant, and one drug treating alcoholism. Of the 28 effi cacy measures used in the CNS product labels, seven (25%) were PRO. The four drugs using PRO endpoints included one antidepressant, one analgesic, one CNS stimulant and one smoking cessation drug. Of the seven PRO used, three were symptom scales, two were global impression scales, one scale measured condition-specifi c health-related quality-of-life, and one scale measured functional impairment. The percentage of approved CNS drugs using PRO as effi cacy endpoints in label claims declined since 2002 (2003-08: 28.5%; 1997-2002: 75%) . CONCLUSIONS: The latter half of the past decade has seen a considerable decrease in the number of CNS drugs that have had PRO-based label claims. Symptoms scales are the prominent type of PRO used in CNS drug label claims.
PMH52 EVALUATING CENTRAL NERVOUS SYSTEM DRUG LABELS FOR PATIENT-REPORTED OUTCOMES CLAIMS

PMH53 THE ASSOCIATION OF COPAY BURDEN AND OUTCOMES AMONG PATIENTS WITH SCHIZOPHRENIA
Kim E 1 , Gupta S 2 , Bogle SC 2 , Chen CC 1 , Whitehead R 3 , Bates JA 1 1 Bristol-Myers Squibb, Plainsboro, NJ, USA, 2 Consumer Health Sciences, Princeton, NJ, USA, 3 Otsuka America Pharmaceutical, Inc, Rockville, MD, USA OBJECTIVES: To identify the clinical outcomes associated with self-perceived copay burden among patients with schizophrenia. METHODS: Data were taken from a nationwide survey of adults (age 18 ) with a self-reported diagnosis of schizophrenia. The survey was fi elded from December 2007 to February 2008. Data were collected through both self-reported questionnaires administered on-site, and via the Internet. Inclusion criteria for analysis were no exposure to clozapine, no use of a depot injection of an antipsychotic, and currently using a second generation antipsychotic (SGA). Outcomes included emergency room (ER) visits, hospitalization, suicide attempt, missed work (among employed patients), as well as experiencing severe distress defi ned as a score of 0-60 on the Psychological General Well Being (PGWB) scale. Assessment of the effects of self-perceived copay burden on outcomes was calculated using logistic regression models. Demographics, substance use, concomitant psychotropic medications, comorbidity, and health insurance were controlled for in the models. RESULTS: Of the patients who met the inclusion criteria (n 351), 39% (n 137) self-reported experiencing copay burden. Adjusting for covariates, patients who experienced copay burden were more likely to use the ER [OR 2.157 [OR 7.193; 95% CI: (2.554, 20.256 ); p 0.001]. CONCLUSIONS: Among patients with schizophrenia using SGAs, greater copay burden was associated with increased ER visits, hospitalization, suicide attempts, missed work, and psychological distress. Patient's health care use and psychological well being are likely to benefi t from less restrictive formularies that reduce copay burden for antipsychotic medication.
